Business Wire

CA-QUANERGY-SYSTEMS

26.9.2018 16:11:02 CEST | Business Wire | Press release

Share
Quanergy Announces Availability of Power Over Ethernet for M8 LiDAR Sensor

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced the availability of its M8 LiDAR sensor with Power over Ethernet (PoE+). This new connector interface, designed specifically for the security market, allows the sensor to be easily installed and integrated with new or existing security systems, without costly custom wiring to power the LiDAR sensor.

Surveillance systems leverage PoE to transmit power and data across the sensor and system. The IEEE 802.3at (PoE+) specification provides more power to PoE-powered devices and allows for a broader range of devices to be easily integrated into a network via standard Ethernet cable. The release of the M8 with PoE+ allows for a simpler, more flexible installation of LiDAR-based security systems. Its plug-and-play usability permits customers to make use of their existing security infrastructure when upgrading to a LiDAR-based security solution, leading to significant savings in implementation cost and time.

The M8 sensor’s long range and 360 degree field of view enables systems to detect and track potential intruders before they physically breach a perimeter. The M8 PoE+ provides a signifcantly smaller overall footprint than other PoE+ sensors and radars. Unlike traditional security camera technology, the M8 operates successfully in challenging weather environments as well as in the dark. Paired with Quanergy’s proprietary LiDAR perception software, QORTEX for Security™, the M8 can be used as a standalone solution, or as an integrated component of a larger security system.

“We built the M8 with Power over Ethernet to enable our security customers to implement a LiDAR-based security system as easily as they would a camera-based surveillance system,” said Dr. Louay Eldada, CEO of Quanergy. “Our LiDAR sensors lead the industry in price, performance, and reliability. With PoE+, our customers can easily harness the power of LiDAR to ensure the highest level of security and awareness around vulnerable perimeters, protecting critical infrastructure such as airports, national borders, subways, power plants, oil fields and prisons.”

In addition to offering its technology as a standalone security solution, Quanergy deploys its technology in partnership with public safety and security technology firms (system integrators or SI) such as Vision Logic, many of whom are already using Power over Ethernet to connect other surveillance tools, such as IP cameras. This new availability allows SIs to flexibly incorporate Quanergy’s LiDAR technology into existing security systems, reducing installation time and costs.

“Integrating LiDAR technology into our video surveillance and facial recognition systems enables us to offer an unparalleled level of security and awareness to our customers,” said John Walsh, co-founder of Vision Logic. Graham Conran, co-founder and CEO of Vision Logic added “With Power over Ethernet, we can more easily incorporate Quanergy’s industry leading LiDAR sensors into our public safety and security platforms, tailoring our solutions to each of our customers’ needs.”

The M8 with PoE+ will be on display at two leading security industry events. Quanergy will be exhibiting at GSX in Las Vegas, September 25-27, in booth #2885. At Security Essen in Germany, September 26-28, the sensor will be in both the Milestone Systems and Genetec booths in Hall 5. Genetec will be in booth #5G30 and Miletsone will be in booth #5F10. General availability of the M8 sensor with PoE+ is November 2018.

About Quanergy Systems, Inc.

Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers smart sensing solutions. It is the leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D spatial data and object detection, identification, classification and tracking. Its sensors are disruptive in price, performance, reliability, size, weight and power. Its solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, smart spaces and 3D-aware smart devices for improved safety, efficiency and quality of life. For more information, visit www.quanergy.com .

Contact:

Quanergy Systems, Inc. Ann Gargiulo, +1-408-245-9500 Director of Marketing Communications media@quanergy.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye